-
1
-
-
84928580276
-
Studies on prostatic cancer: I the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
C. Huggins, C.V. Hodges Studies on prostatic cancer: I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293
-
(1941)
Cancer Res
, vol.1
, pp. 293
-
-
Huggins, C.1
Hodges, C.V.2
-
2
-
-
67649678763
-
Complications of androgen deprivation therapy in prostate cancer
-
A. Schwandt, J.A. Garcia Complications of androgen deprivation therapy in prostate cancer Curr Opin Urol 19 2009 322
-
(2009)
Curr Opin Urol
, vol.19
, pp. 322
-
-
Schwandt, A.1
Garcia, J.A.2
-
3
-
-
66649136169
-
Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer
-
L.G. Taylor, S.E. Canfield, X.L. Du Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer Cancer 115 2009 2388
-
(2009)
Cancer
, vol.115
, pp. 2388
-
-
Taylor, L.G.1
Canfield, S.E.2
Du, X.L.3
-
4
-
-
70449523110
-
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature
-
P.A. Abrahamsson Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49
-
(2010)
Eur Urol
, vol.57
, pp. 49
-
-
Abrahamsson, P.A.1
-
5
-
-
48849104783
-
Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: Interim analysis of prognostic markers affecting initial response to androgen deprivation
-
A.J. Salonen, J. Viitanen, S. Lundstedt Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation J Urol 180 2008 915
-
(2008)
J Urol
, vol.180
, pp. 915
-
-
Salonen, A.J.1
Viitanen, J.2
Lundstedt, S.3
-
6
-
-
0142228727
-
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: An EORTC feasibility study
-
W. Albrecht, L. Collette, C. Fava Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study Eur Urol 44 2003 505
-
(2003)
Eur Urol
, vol.44
, pp. 505
-
-
Albrecht, W.1
Collette, L.2
Fava, C.3
-
7
-
-
12244271448
-
A 10-year clinical experience with intermittent hormonal therapy for prostate cancer
-
D. Prapotnich, K. Fizazi, B. Escudier A 10-year clinical experience with intermittent hormonal therapy for prostate cancer Eur Urol 43 2003 233
-
(2003)
Eur Urol
, vol.43
, pp. 233
-
-
Prapotnich, D.1
Fizazi, K.2
Escudier, B.3
-
8
-
-
41149171703
-
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)
-
U.E. Studer, L. Collette, P. Whelan Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941
-
(2008)
Eur Urol
, vol.53
, pp. 941
-
-
Studer, U.E.1
Collette, L.2
Whelan, P.3
-
9
-
-
0032991677
-
Intermittent complete androgen blockade in metastatic prostate cancer
-
J. Rambeaud Intermittent complete androgen blockade in metastatic prostate cancer Eur Urol 35 1999 32
-
(1999)
Eur Urol
, vol.35
, pp. 32
-
-
Rambeaud, J.1
-
10
-
-
53749103325
-
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
-
B. Seruga, I.F. Tannock Intermittent androgen blockade should be regarded as standard therapy in prostate cancer Nat Clin Pract Oncol 5 2008 574
-
(2008)
Nat Clin Pract Oncol
, vol.5
, pp. 574
-
-
Seruga, B.1
Tannock, I.F.2
-
11
-
-
34548443017
-
The role of intermittent androgen deprivation in prostate cancer
-
L. Boccon-Gibod, P. Hammerer, S. Madersbacher The role of intermittent androgen deprivation in prostate cancer BJU Int 100 2007 738
-
(2007)
BJU Int
, vol.100
, pp. 738
-
-
Boccon-Gibod, L.1
Hammerer, P.2
Madersbacher, S.3
-
12
-
-
77957315589
-
Intermittent androgen deprivation therapy: Redefining the standard of care?
-
N.D. Shore, E.D. Crawford Intermittent androgen deprivation therapy: redefining the standard of care? Rev Urol 12 2010 1
-
(2010)
Rev Urol
, vol.12
, pp. 1
-
-
Shore, N.D.1
Crawford, E.D.2
-
13
-
-
0000368040
-
Intermittent androgen suppression for prostate cancer: Rationale and clinical experience
-
M. Gleave, S.L. Goldenberg, N. Bruchovsky Intermittent androgen suppression for prostate cancer: rationale and clinical experience Prostate Cancer Prostatic Dis 1 1998 289
-
(1998)
Prostate Cancer Prostatic Dis
, vol.1
, pp. 289
-
-
Gleave, M.1
Goldenberg, S.L.2
Bruchovsky, N.3
-
14
-
-
0034903581
-
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy
-
G.D. Grossfeld, E.J. Small, D.P. Lubeck Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy Urology 58 2001 56
-
(2001)
Urology
, vol.58
, pp. 56
-
-
Grossfeld, G.D.1
Small, E.J.2
Lubeck, D.P.3
-
15
-
-
65049090443
-
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group
-
F.E. Calais da Silva, A.V. Bono, P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269
-
(2009)
Eur Urol
, vol.55
, pp. 1269
-
-
Calais Da Silva, F.E.1
Bono, A.V.2
Whelan, P.3
-
16
-
-
33748465540
-
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162)
-
M. Hussain, C.M. Tangen, C. Higano Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984
-
(2006)
J Clin Oncol
, vol.24
, pp. 3984
-
-
Hussain, M.1
Tangen, C.M.2
Higano, C.3
-
17
-
-
70349485852
-
A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: Oncological results
-
D. Prapotnich, X. Cathelineau, F. Rozet A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results World J Urol 27 2009 627
-
(2009)
World J Urol
, vol.27
, pp. 627
-
-
Prapotnich, D.1
Cathelineau, X.2
Rozet, F.3
-
18
-
-
12444317207
-
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a prospective randomized multicenter trial
-
J. de Leval, P. Boca, E. Yousef Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial Clin Prostate Cancer 1 2002 163
-
(2002)
Clin Prostate Cancer
, vol.1
, pp. 163
-
-
De Leval, J.1
Boca, P.2
Yousef, E.3
-
19
-
-
0033762705
-
A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy
-
R.J. Nejat, H.H. Rashid, E. Bagiella A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy J Urol 164 2000 1891
-
(2000)
J Urol
, vol.164
, pp. 1891
-
-
Nejat, R.J.1
Rashid, H.H.2
Bagiella, E.3
-
20
-
-
17144414951
-
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy
-
J.L. Gulley, W.D. Figg, S.M. Steinberg A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy J Urol 173 2005 1567
-
(2005)
J Urol
, vol.173
, pp. 1567
-
-
Gulley, J.L.1
Figg, W.D.2
Steinberg, S.M.3
-
21
-
-
33746387985
-
Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer
-
N.A. Spry, L. Kristjanson, B. Hooton Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer Eur J Cancer 42 2006 1083
-
(2006)
Eur J Cancer
, vol.42
, pp. 1083
-
-
Spry, N.A.1
Kristjanson, L.2
Hooton, B.3
-
22
-
-
45849110316
-
Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: A randomised study
-
J. Irani, O. Celhay, J. Hubert Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study Eur Urol 54 2008 382
-
(2008)
Eur Urol
, vol.54
, pp. 382
-
-
Irani, J.1
Celhay, O.2
Hubert, J.3
-
23
-
-
80053201964
-
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation
-
D. Keizman, P. Huang, E.S. Antonarakis The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation Prostate 71 2011 1608
-
(2011)
Prostate
, vol.71
, pp. 1608
-
-
Keizman, D.1
Huang, P.2
Antonarakis, E.S.3
|